Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31683032 | 0.87 | MAPT (0.43) | NPC1MAPTKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL7806512 | 0.80 | LOXL2 (0.60) | NPC1FLT3RAB9ASMN1; SMN2LOXL2 | |
| SCHEMBL15157277 | 0.80 | MAOA (0.49) | FLT3KDM4ESMN1; SMN2HSD17B10LMNA | |
| SCHEMBL1601958 | 0.80 | PIM1 (0.50) | RAB9AGPR55POLBLMNATSHR | |
| SCHEMBL11619290 | 0.79 | CYP1A2 (0.46) | CYP1A2LOXL2GPR55POLBSTS | |
| SCHEMBL11673340 | 0.76 | GPR55 (0.71) | KDM4EACHEGPR55CA2HTR1A | |
| SCHEMBL4689215 | 0.75 | FLT3 (0.55) | NPC1FLT3MAPTKDM4ERAB9A | |
| SCHEMBL28282594 | 0.75 | FLT3 (0.50) | NPC1FLT3MAPTKDM4ERAB9A | |
| SCHEMBL8805208 | 0.74 | KDM4E (0.47) | NPC1MAPTKDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL8179958 | 0.74 | MEN1 (0.53) | NPC1MAPTRAB9ASMN1; SMN2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-01-13 | — | — | US | disclosed |
| EP-1463507-A1 | THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003053446-A1 | THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-03 | — | — | WO | disclosed |
| US-6143772-A | ANTIDEPRESSANTS AND TRANQUILIZERS FORMED FROM REACTION OF BORON TRIBROMIDE AND CARBAMYL SUBSTITUTED BENZOFURAN | SYNTHELABO (FR) | 2000-11-07 | — | — | US | disclosed |
| EP-0859775-A1 | COMPOUNDS DERIVED FROM 3-(BENZOFURAN-5-YL)OXAZOLIDIN-2-ONE, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF | SYNTHELABO (FR) | 1998-08-26 | — | — | EP | disclosed |
| WO-1997017346-A1 | COMPOUNDS DERIVED FROM 3-(BENZOFURAN-5-YL)OXAZOLIDIN-2-ONE, PREPARATION METHOD THEREFOR AND THERAPEUTICAL USE THEREOF | SYNTHELABO (FR) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | ERBB2, ERBB4, ERBB3 | NPC1 4535/4885FLT3 131/4885MAPT 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.